 Bradley Dixon
Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atypical Hemolytic Uremic Syndrome | 6 | 2023 | 18 | 2.020 |
Why?
| | Kidney Diseases | 4 | 2022 | 354 | 1.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2023 | 667 | 0.660 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2019 | 12 | 0.650 |
Why?
| | Acute Kidney Injury | 4 | 2023 | 646 | 0.490 |
Why?
| | Autoimmunity | 1 | 2020 | 822 | 0.480 |
Why?
| | Autoantibodies | 2 | 2020 | 1360 | 0.440 |
Why?
| | Glomerulonephritis, Membranoproliferative | 2 | 2022 | 13 | 0.430 |
Why?
| | Lupus Nephritis | 2 | 2022 | 52 | 0.400 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.370 |
Why?
| | RecQ Helicases | 1 | 2008 | 10 | 0.320 |
Why?
| | DNA Damage | 1 | 2011 | 357 | 0.310 |
Why?
| | Cell Cycle | 1 | 2011 | 546 | 0.300 |
Why?
| | Complement System Proteins | 3 | 2022 | 288 | 0.300 |
Why?
| | Thrombotic Microangiopathies | 2 | 2020 | 13 | 0.300 |
Why?
| | Purines | 1 | 2008 | 159 | 0.290 |
Why?
| | Escherichia coli Proteins | 1 | 2008 | 164 | 0.280 |
Why?
| | Pyrimidines | 1 | 2008 | 376 | 0.250 |
Why?
| | Cell Line | 1 | 2011 | 2651 | 0.250 |
Why?
| | Complement Inactivating Agents | 2 | 2023 | 41 | 0.230 |
Why?
| | Arthritis, Juvenile | 1 | 2022 | 42 | 0.210 |
Why?
| | Nephrology | 1 | 2022 | 48 | 0.200 |
Why?
| | Complement Factor B | 1 | 2023 | 100 | 0.200 |
Why?
| | DNA | 1 | 2008 | 1356 | 0.190 |
Why?
| | Rheumatology | 1 | 2022 | 89 | 0.190 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2019 | 519 | 0.190 |
Why?
| | Critical Illness | 2 | 2023 | 645 | 0.170 |
Why?
| | Renal Dialysis | 2 | 2022 | 369 | 0.170 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 221 | 0.160 |
Why?
| | Plasma Exchange | 1 | 2019 | 12 | 0.160 |
Why?
| | Renal Replacement Therapy | 1 | 2019 | 68 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.160 |
Why?
| | Plasmapheresis | 1 | 2018 | 22 | 0.160 |
Why?
| | Escherichia coli Infections | 1 | 2019 | 102 | 0.150 |
Why?
| | Fluid Therapy | 1 | 2019 | 122 | 0.150 |
Why?
| | Blood Component Transfusion | 1 | 2018 | 76 | 0.150 |
Why?
| | Autoimmune Diseases | 1 | 2020 | 395 | 0.140 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 28 | 0.140 |
Why?
| | Erythrocyte Transfusion | 1 | 2019 | 187 | 0.140 |
Why?
| | Streptococcal Infections | 1 | 2019 | 132 | 0.140 |
Why?
| | Humans | 16 | 2023 | 115589 | 0.140 |
Why?
| | Disease Management | 1 | 2020 | 563 | 0.140 |
Why?
| | Plasma | 1 | 2018 | 213 | 0.140 |
Why?
| | Kidney | 1 | 2022 | 1207 | 0.130 |
Why?
| | Caregivers | 1 | 2022 | 713 | 0.130 |
Why?
| | Cytomegalovirus Infections | 1 | 2017 | 182 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1357 | 0.120 |
Why?
| | Child | 9 | 2023 | 18489 | 0.110 |
Why?
| | Kidney Transplantation | 1 | 2019 | 558 | 0.110 |
Why?
| | Complement Factor D | 2 | 2022 | 27 | 0.110 |
Why?
| | Complement Pathway, Alternative | 1 | 2013 | 114 | 0.100 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2011 | 14 | 0.090 |
Why?
| | Prognosis | 1 | 2019 | 3339 | 0.090 |
Why?
| | Complement Activation | 2 | 2022 | 343 | 0.080 |
Why?
| | Kanamycin Resistance | 1 | 2008 | 2 | 0.080 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2008 | 27 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2011 | 197 | 0.080 |
Why?
| | Plasmids | 1 | 2008 | 345 | 0.070 |
Why?
| | Biomarkers | 3 | 2023 | 3467 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2008 | 309 | 0.070 |
Why?
| | DNA Replication | 1 | 2008 | 203 | 0.070 |
Why?
| | Prospective Studies | 3 | 2023 | 6264 | 0.060 |
Why?
| | Mice, Transgenic | 1 | 2011 | 1970 | 0.060 |
Why?
| | Risk Factors | 1 | 2019 | 8697 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1153 | 0.060 |
Why?
| | Child, Preschool | 4 | 2021 | 9133 | 0.060 |
Why?
| | Repressor Proteins | 1 | 2008 | 369 | 0.060 |
Why?
| | Nucleic Acid Conformation | 1 | 2008 | 672 | 0.060 |
Why?
| | Adolescent | 5 | 2022 | 17890 | 0.060 |
Why?
| | Escherichia coli | 1 | 2008 | 730 | 0.060 |
Why?
| | Proteinuria | 1 | 2022 | 78 | 0.050 |
Why?
| | Atrophy | 1 | 2022 | 152 | 0.050 |
Why?
| | Complement C3 | 1 | 2022 | 190 | 0.050 |
Why?
| | Complement C5 | 1 | 2020 | 74 | 0.050 |
Why?
| | Fibrosis | 1 | 2022 | 457 | 0.040 |
Why?
| | Gelatinases | 1 | 2019 | 6 | 0.040 |
Why?
| | Cystatin C | 1 | 2019 | 61 | 0.040 |
Why?
| | Allografts | 1 | 2019 | 127 | 0.040 |
Why?
| | Mutation | 1 | 2008 | 3364 | 0.040 |
Why?
| | Female | 5 | 2022 | 59913 | 0.040 |
Why?
| | Adult | 3 | 2023 | 30719 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 622 | 0.040 |
Why?
| | Creatinine | 1 | 2019 | 430 | 0.040 |
Why?
| | Young Adult | 2 | 2022 | 10470 | 0.040 |
Why?
| | Kidney Function Tests | 1 | 2017 | 141 | 0.030 |
Why?
| | Infant | 2 | 2021 | 7979 | 0.030 |
Why?
| | Male | 4 | 2022 | 55949 | 0.030 |
Why?
| | Mice | 1 | 2011 | 15052 | 0.030 |
Why?
| | Algorithms | 1 | 2021 | 1490 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2829 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4944 | 0.030 |
Why?
| | Quality of Life | 1 | 2023 | 2385 | 0.030 |
Why?
| | Gene Deletion | 1 | 2013 | 355 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2578 | 0.020 |
Why?
| | Animals | 1 | 2011 | 32102 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1787 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 12608 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2017 | 9159 | 0.010 |
Why?
| | Middle Aged | 1 | 2023 | 26998 | 0.010 |
Why?
|
|
Dixon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|